Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02939547 · ClinicalTrials.gov registry record · Phase 1
Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)
A Phase 1 study of Niemann-Pick Disease, Type C1, sponsored by Cyclo Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 2
- Study locations
NCT02939547 is a Phase 1 study of Niemann-Pick Disease, Type C1 that has completed, run by Cyclo Therapeutics. The registered enrollment target is 13 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT02939547, a Phase 1 study of Niemann-Pick Disease, Type C1, has completed, sponsored by Cyclo Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is being conducted to find out whether Trappsol® Cyclo™, an experimental treatment for people with Niemann Pick disease Type C (NPC-1) is safe at 2 different dose levels and what effects it has on people who have this condition. NPC-1 is caused by a defect in the protein which is important for the transport of fatty substances like cholesterol out of cells. Without this protein, fats build up in the cells ultimately leading to organ damage. The way in which this experimental treatment works is not fully understood but laboratory experiments have shown that it can potentially remove cholesterol build up from the cells in people who have NPC-1. Approximately 12 patients will be asked to take part in this research study for up to 20 weeks (w) in total (including screening. treatment and follow-up). Recruitment is expected to take 6- 9 months.Patients who take part will receive treatment by an intravenous infusion every two weeks. The study will look at what the body does to the drug as well as what the drug does to the body by taking and examining blood and urine samples. A sample(s) of cerebrospinal fluid (CSF) will be taken by lumbar puncture during the first treatment dose and may be collected during subsequent doses. Liver and skin biopsy specimens will be taken to assess filipin staining. Cholesterol metabolism will be investigated in liver samples and splenic and hepatic elasticity will be assessed by ultrasound. Patients will also have their hearing tested, be asked questions by their doctor as well completing questionnaires to help assess any changes in their condition during treatment.This study is being sponsored and funded by CTD holdings Inc. It is planned to be run in the USA,.
Conditions Studied
Interventions
- DRUG Hydroxypropyl-beta-cyclodextrin
Study Locations (2)
California
- UCSF Benioff Children's Hospital Oakland - Oakland
New Jersey
- Atlantic Health System/Morristown Medical Center - Morristown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-10-11 |
| Est. Completion | 2020-02-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02939547
The ClinicalTrials.gov registry entry for NCT02939547 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cyclo Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Niemann-Pick Disease, Type C1 appearing as the primary indexed condition, and to 1 intervention - of which Hydroxypropyl-beta-cyclodextrin is the first listed.
NCT02939547 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02939547 about?
NCT02939547 is a clinical study titled "Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)". This research study is being conducted to find out whether Trappsol® Cyclo™, an experimental treatment for people with Niemann Pick disease Type C (NPC-1) is safe at 2 different dose levels and what effects it has on people who have this condition. NPC-1 is caused by a defect in the protein which is...
What is the current status of trial NCT02939547?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2017-10-11. Estimated completion is 2020-02-10.
What conditions does trial NCT02939547 study?
This clinical trial studies the following conditions: Niemann-Pick Disease, Type C1.
What interventions are being tested in trial NCT02939547?
The interventions under investigation include: Hydroxypropyl-beta-cyclodextrin (DRUG).
Who is sponsoring clinical trial NCT02939547?
This trial is sponsored by Cyclo Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02939547 being conducted?
This trial has 2 study locations across California, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Niemann-Pick Disease, Type C1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.